Skip to content
Catalyst

PapersPMID:24917198

A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression.

Neuropsychopharmacology2014The record ↗

  1. Finding, very limited evidenceraisesDepression remission rate

What moved

1 findingHow to read these marks →
  • “Depression remission rates were greater in the pregnenolone group (61%) compared with the placebo group (37%), as assessed by the IDS-SR (χ(2)(1)=3.99, p=0.046), but not the HRSD.”
    Study
    RCT
    Duration
    3 months
    Dose studied
    pregnenolone titrated to 500 mg/day, add-on therapy
    Population
    Adults with bipolar disorder in a depressed mood state, pregnenolone or placebo added to ongoing therapy for 12 weeks; remission as assessed by the Inventory of Depressive Symptomatology-Self-Report (IDS-SR), not by the HRSD

Study record

Design
randomised controlled trial
Species
human
Population
Adults with bipolar disorder, depressed mood state
Participants
80
Comparator
placebo
Duration
84 days
Endpoints measured
7